Cancer Microbiome Sequencing Market: Current Analysis and Forecast (2021-2027)

Cancer Microbiome Sequencing Market: Current Analysis and Forecast (2021-2027)

Global Cancer Microbiome Sequencing Market is anticipated to grow with an elevated CAGR of around 20% over the forecast period (2021-2027). The microbiome is the collection of all the gene sequences from a microbial community in the human body that contributes to human health and the body. Sequencing allows the profiling of microbial communities that may be targeted for developing new therapeutic approaches to cancer.

The cancer microbiome sequencing market has been growing on account of various factors including the growing emphasis on the microbiome’s potential in the field of cancer and surging incidences of cancer across the globe. For instance, the number of cancer cases in the US will increase 49% each year, from 1,534,500 in 2015 to 2,286,300 in 2050, with the largest percentage increase among adults aged ≥75 years, as per the predictions by CDC. This exponential increase in cancer prevalence has created a buzz among biotechnology companies for investing in the development of novel diagnostic tools based on the microbiome that will offer early cancer detection.

Additionally, promulgating strategic alliances among industry players for accelerating microbiome research is another prominent factor that is significantly driving the cancer microbiome sequencing market globally. For example, in June 2021, Illumina and Microba Life Sciences came into a partnership to advance their understanding of the human gut microbiome in human health and disease. Illumina’s revolutionary NGS tools and Microba’s high-quality proprietary gut microbiome analysis platform will generate the accurate metagenomic data that researchers require to fuel discoveries.

Thermo Fisher Scientific Inc., CD Genomics, Eurofins Scientific, Illumina, Inc., Prescient Medicine Holdings, Inc., QIAGEN N.V., Micronoma Inc., Oxford Nanopore Technologies, Zymo Research Corporation, OraSure Technologies, Inc., are some of the prominent players operating in the cancer microbiome sequencing market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with cancer microbiome sequencing products.

Insights Presented in the Report
"Amongst Offerings, products segment holds the major share”

Based on offerings, the cancer microbiome sequencing market is divided into products & services. The products segment accounted for the leading market share in 2020 it is estimated that it will exhibit the highest CAGR during the forecast. The products segment is further sub-segmented into kits & assays and software. The growth of this segment can be attributed to the rising number of sequencing procedures and the launch of new and advanced assay kits and software. However, the services segment is expected to grow considerably during the projected timeframe.
"Amongst Technology, next-generation sequencing segment holds the major share”

Based on technology, the cancer microbiome sequencing market is segmented into next-generation sequencing (NGS) and polymerase chain reaction. The next-generation sequencing segment occupied a substantial share of the cancer microbiome sequencing market in 2020 and it is expected to grow considerably in the upcoming years as NGS allows clinicians to test various cancer genes simultaneously. Furthermore, the growing adoption of next-generation sequencing in clinical oncology to advance personalized cancer treatment is also contributing to the growth of the segment.
"Amongst Application, colorectal cancer segment holds the major share”

Based on application, the market is fragmented into colorectal cancer, cervical cancer, oral cancer, and others. In 2020, the colorectal cancer segment grabbed a considerable market share, and it is expected to grow at a significant CAGR during the forecast period. The growth of this segment is attributed to the rising incidences of colorectal cancer globally. For instance, according to the report by the International Agency for Research on Cancer, the incidences of colon cancer were nearly 1.1 million in 2019 and it is expected to increase to over 1.5 million by 2030.
"Amongst End-Users, hospitals & diagnostic laboratories segment holds the major share”

Based on end-users, the market is fragmented into academic & research institutes, pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, and others. In 2020, the hospitals & diagnostic laboratories segment grabbed a considerable market share, and it is expected to grow at a significant CAGR during the forecast period as the majority of the sequencing test takes place in laboratories for detecting various diseases. However, the academic & research institutes segment is expected to grow significantly in the upcoming years.
"North America represents one of the largest markets of cancer microbiome sequencing market”

For a better understanding of the market dynamics of the cancer microbiome sequencing market, a detailed analysis was conducted for different regions across the globe including North America (the U.S, Canada, and the Rest of North America), Europe (Germany, France, Spain, United Kingdom, Italy, and Rest of Europe), Asia-Pacific (China, India, Australia, Japan, and Rest of APAC), Rest of World has been conducted. North America constitutes a major market for the cancer microbiome sequencing market industry and generated revenue of USD XX Million in 2020 owing to growing healthcare expenditure and the presence of industry players in the region. Reasons to buy this report:

  • The study includes market sizing and forecasting analysis validated by authenticated key industry experts
  • The report presents a quick review of overall industry performance at one glance
  • The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments
  • Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry
  • The study comprehensively covers the market across different segments
  • Deep dive regional level analysis of the industry


1 MARKET INTRODUCTION
1.1 Market Definitions
1.2 Objective of the Study
1.3 Limitation
1.4 Stake Holders
1.5 Currency Used in Report
1.6 Scope of the Global Cancer Microbiome Sequencing Study
2 RESEARCH METHODOLOGY OR ASSUMPTION
2.1 Research Methodology for the Global Cancer Microbiome Sequencing Market
2.1.1 Main Objective of the Global Cancer Microbiome Sequencing Market
3 MARKET SYNOPSIS
4 EXECUTIVE SUMMARY
5 COVID-19 IMPACT
6 GLOBAL CANCER MICROBIOME SEQUENCING MARKET REVENUE
7 MARKET INSIGHTS BY OFFERINGS
7.1 Products
7.1.1 Kits & Assays
7.1.2 Software
7.3 Services
8 MARKET INSIGHTS BY TECHNOLOGY
8.1 Next-Generation Sequencing
8.1.1 Sequencing by Synthesis
8.1.2 Sequencing by Ligation
8.1.3 Others
8.2 Polymerase Chain Reaction
9 MARKET INSIGHTS BY APPLICATION
9.1 Colorectal Cancer
9.2 Cervical Cancer
9.3 Oral cancer
9.4 Others
10 MARKET INSIGHTS BY END-USERS
10.1 Academic and Research Institutes
10.2 Pharmaceutical and Biotechnology Companies
10.3 Hospitals and Diagnostic Laboratories
10.4 Others
11 MARKET INSIGHTS BY REGION
11.1 NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET
11.1.1 United States
11.1.2 Canada
11.1.3 Rest of North America
11.2 EUROPE CANCER MICROBIOME SEQUENCING MARKET
11.2.1 Germany
11.2.2 France
11.2.3 United Kingdom
11.2.4 Spain
11.2.5 Italy
11.2.6 Rest of Europe
11.3 ASIA PACIFIC CANCER MICROBIOME SEQUENCING MARKET
11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 Australia
11.3.5 Rest of Asia Pacific
11.4 REST OF THE WORLD CANCER MICROBIOME SEQUENCING MARKET
12 CANCER MICROBIOME SEQUENCING MARKET DYNAMICS
12.1 Market Drivers
12.2 Market Challenges
12.3 Impact Analysis
13 CANCER MICROBIOME SEQUENCING MARKET OPPORTUNITIES
14 CANCER MICROBIOME SEQUENCING MARKET TRENDS & INSIGHTS
15 LEGAL & REGULATORY FRAMEWORK
16 DEMAND AND SUPPLY SIDE ANALYSIS
16.1 Demand Side Analysis
16.2 Supply Side Analysis
16.2.1 Top Product Launches
16.2.2 Top Business Partnerships
16.2.3 Top Merger & Acquisitions
17 VALUE CHAIN ANALYSIS
18 COMPETITIVE SCENARIO
18.1 Porter’s Five forces analysis
18.1.1 Bargaining power of Supplier
18.1.2 Bargaining power of Buyer
18.1.3 Industry Rivalry
18.1.4 Availability of Substitute
18.1.5 Threat of new Entrants
18.2 Competitive Landscape
18.2.1 Company Shares, By Revenue
19 COMPANY PROFILED
19.1 Thermo Fisher Scientific Inc.
19.1.1 Key Facts
19.1.2 Business Description
19.1.3 Key Product/Services Offerings
19.1.4 Growth Strategy
19.1.5 SWOT Analysis
19.1.6 Key Financials
19.1.6.1 Revenue Split
19.1.6.2 Financial Overview of Thermo Fisher Scientific Inc.
19.1.7 Recent Developments
19.1.7.1 Product Launch
19.1.7.2 Partnerships
19.1.7.3 Business Expansion and Investments
19.1.7.4 Merger and Acquisition
19.2 CD Genomics
19.3 Eurofins Scientific
19.4 Illumina, Inc.
19.5 Prescient Medicine Holdings, Inc.
19.6 QIAGEN N.V.
19.7 Micronoma Inc.
19.8 Oxford Nanopore Technologies
19.9 Zymo Research Corporation
19.10 OraSure Technologies, Inc.
20 DISCLAIMER

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings